Active, not recruitingPHASE1, PHASE2NCT06109181
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
Studying Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lexeo Therapeutics
- Principal Investigator
- LEXEO Clinical TrialsLexeo Therapeutics
- Intervention
- LX2020(genetic)
- Enrollment
- 10 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2027
Study locations (5)
- Stanford University, Stanford, California, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- University of Michigan, Ann Arbor, Michigan, United States
- University of Rochester, Rochester, New York, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06109181 on ClinicalTrials.govOther trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07050160Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic VariantLexeo Therapeutics
- RECRUITINGPHASE2NCT06174220Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic CardiomyopathyHamilton Health Sciences Corporation
See all trials for Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant →